Cytokines reinstate NK cell-mediated cancer Immunosurveillance

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 4687-4689

  Zitvogel, Laurence ^a,b,c,d   Kroemer, Guido ^a,e,f,g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University Paris XI   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Center of Clinical Investigations in Biotherapies of Cancer CICBT 507   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HETERODIMER; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; INTERLEUKIN 2;

CANCER IMMUNOLOGY; CELL FUNCTION; CLONAL ANERGY; CYTOKINE RELEASE; HUMAN; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NONHUMAN; REVIEW; TUMOR CELL; ANIMAL; IMMUNOLOGY;

ANIMALS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-2; KILLER CELLS, NATURAL;

EID: 84908631985     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78531     Document Type: Review

References (21)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49.
2. Narni-Mancinelli E, Ugolini S, Vivier E. Tuning the threshold of natural killer cell responses. Curr Opin Immunol. 2013;25(1):53-58.
3. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675-678.
4. Ardolino M, et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest. 2014;124(11):4781-4794.
5. Levin AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature. 2012;484(7395):529-533.
6. Grufman P, Kärre K. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol. 2000;30(4):1088-1093.
7. Sun JC, Lanier LL. Cutting edge: viral infection breaks NK cell tolerance to "missing self". J Immunol. 2008;181(11):7453-7457.
8. Mamessier E, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609-3622.
9. Messaoudene M, et al. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 2014;74(1):81-92.
10. Borg C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114(3):379-388.
11. Remark R, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19(15):4079-4091.
12. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer. 2006;118(1):129-138.
13. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117-158.
14. Jäger E, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997;71(2):142-147.
15. Rusakiewicz S, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3499-3510.
16. Romagné F, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667-2677.
17. Senovilla L, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012;1(8):1323-1343.
18. Vacchelli E, et al. Trial Watch: immunostimulatory cytokines. Oncoimmunology. 2012;1(4):493-506.
19. Tarhini AA, et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009;115(4):859-868.
20. Simpkins F, et al. Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin- 18 in recurrent ovarian cancer: A phase I dose-escalation study. Cancer Immunol Res. 2013;1(3):168-178.
21. Kellner C, Gramatzki M, Peipp M. Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype. Oncoimmunology. 2013;2(6):e24481.